These results are consistent with studies demonstrating SGLT2 inhibitors’ protective effects in cardiovascular models independent of diabetes, such as ischemic cardiomyopathy, where benefits are attributed to improved myocardial energetics and reduced oxidative stress [28]. Here, SLC5A2 is linked to ischemic cardiomyopathy.